The PGen Study

The rapid identification of genetic risk factors for common, complex diseases poses great opportunities and challenges for public health. Genetic information is increasingly being utilized as part of commercial efforts, including personal genomic testing, to provide consumers with genetic risk information related to common diseases. Few empirical data have been gathered to understand the characteristics … Continued


Plenary presentation at the Advances in Genome Biology and Technology Precision Health Meeting

AGBT Precision Health Conference
September 2018
Dr. Robert C. Green speaks at the 2018 Advances in Genome Biology and Technology (AGBT) Precision Health Conference in San Diego, California about our efforts to gather empirical data on genome sequencing healthy individuals. Watch to learn more about G2P’s MilSeq, BabySeq, MedSeq, PeopleSeq, PGen and REVEAL projects. Click here for more on the conference.

How to decipher direct-to-consumer genetic testing

Medical Economics
July 2017
Consumers seek DTC testing for a variety of reasons, “The easiest narrative is that you want to find out if you are at risk for something and hopefully prevent it to improve your health,” says Robert C. Green.

G2P Newsletter May 2017

May 2017
In spring, The New York Times highlighted G2P’s work with REVEAL-SCAN, team members participated in a 10k marathon to raise money for genetic research, and G2P researchers published a new article on direct-to-consumer testing.

Studies probe value and impact of direct-to-consumer genetic testing

Brigham Women's Hospital
December 2016
Despite being on the market for nearly a decade, direct-to-consumer (DTC) genetic testing continues to be controversial among experts and raises concerns among health care providers and regulatory agencies. The NIH-funded “Impact of Personal Genomics (PGen) Study” addresses these concerns by empirically measuring the perceptions and tracking the behaviors of individuals who have received DTC … Continued

Genomes, good news, and you

MIT News
September 2016
An interesting take on direct-to-consumer genetic testing that highlights the result of the PGen study that was conducted by both Brigham and Women’s and MIT.

Study: Many doctors aren’t prepared to advise patients about genetics

Fast Company
March 2016
Direct-to-consumer genetic testing has brought people into doctors offices for second opinions or possible referrals for preventive medicine about potential conditions found when receiving back their results. What patients are finding is that many physicians are skeptical about the use of genetic testing in most cases.

Lab Chat: What people do with their genetic tests

March 2016
After a consumer uses direct personalized genomic testing, they have an option to bring those result to a physicians office. While there is still much skepticism toward direct-to-consumer testing, many doctors dismiss the entirely of the results, while other physicians are more open to using the results to work on personal health for their patients.

Motivations for personalized genetic testing include explaining – not just predicting

Huffington Post
January 2016
A blog post written by Robert Green addresses why people are motivated for continued with personalized genetic testing. “Our study suggested that the motivations for this interest go beyond simply predicting risk… and that for these participants, their fascination with genetics was an attempt to understand the condition that they had,” he says.

Unlocking my genome: Was it worth it?

December 2015
Megan Tirrell seeks out Dr. Robert Green to have her genome sequenced and discusses her experience through the entire process; from meetings with the genetic counselors and learning about cost and variants of unknown significance, to getting her results in her disclosure meetings.

23andMe is jumping back into the market

Medical Xpress
October 2015
Dr. Robert Green shares his insight on the 23andMe initiative and what people should know from these results. “I think this is something that has to be monitored as these services expand their market to less-sophisticated individuals.”

23andMe relaunches direct-to-consumer gene test

Wall Street Journal
October 2015
The FDA has cleared 23andMe to resell their small genetic test kit to consumer to find out if they carry a genetic variant for only some diseases. While not all are available to consumers, many are still interested in knowing about these specific 36 that are included in the test.